MS
Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer and Head of Research and Development
Ironwood PharmaceuticalsTherapeutic Areas
Ironwood Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LINZESS (linaclotide) | Irritable Bowel Syndrome with Constipation (IBS-C) & Chronic Idiopathic Constipation (CIC) | Marketed |
| Apraglutide | Short Bowel Syndrome with Intestinal Failure (SBS-IF) | Phase 3 |
| CNP-104 | Primary Biliary Cholangitis (PBC) | Preclinical |